TY - JOUR
T1 - Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids
AU - Moritaka, Tomonori
AU - Kiura, Katsuyuki
AU - Ueoka, Hiroshi
AU - Tabata, Masahiro
AU - Segawa, Yoshihiko
AU - Shibayama, Takuo
AU - Takigawa, Nagio
AU - Ohnoshi, Taisuke
AU - Harada, Mine
PY - 1998/3/1
Y1 - 1998/3/1
N2 - A cisplatin-resistant cell line, SBC-3/CDDP, was established from a human small-cell lung cancer cell line, SBC-3. The SBC-3/CDDP cells were 13.1-fold more resistant to cisplatin than the parent SBC-3 cells. We investigated the cellular changes of this cell line with regard to the development of resistance to cisplatin. The SBC-3/CDDP cells showed various characteristics as follows: a) increased intracellular glutathione and glutathione S-transferase content b) decreased intracellular accumulation of cisplatin, c) increased topoisomerase I activity and the same topoisomerase II activity as the patent SBC-3 cells, and 4) strong cross-resistance to the platinum analogies and mitomycin C, moderate cross-resistance to 7-ethyl-10-hydroxy-camptothecin (SN-38), 4-hydroperoxy cyclophosphamide, etoposide, Adriamycin and methotrexate, and collateral sensitivity to vinca alkaloids and 5-fluorouracil. From these observations, the SBC-3/CDDP cells could be useful as a well characterized cisplatin-resistant cell line, and the resistance pattern in this cell line will give us much information for eradication of cisplatin-resistant tumor cells.
AB - A cisplatin-resistant cell line, SBC-3/CDDP, was established from a human small-cell lung cancer cell line, SBC-3. The SBC-3/CDDP cells were 13.1-fold more resistant to cisplatin than the parent SBC-3 cells. We investigated the cellular changes of this cell line with regard to the development of resistance to cisplatin. The SBC-3/CDDP cells showed various characteristics as follows: a) increased intracellular glutathione and glutathione S-transferase content b) decreased intracellular accumulation of cisplatin, c) increased topoisomerase I activity and the same topoisomerase II activity as the patent SBC-3 cells, and 4) strong cross-resistance to the platinum analogies and mitomycin C, moderate cross-resistance to 7-ethyl-10-hydroxy-camptothecin (SN-38), 4-hydroperoxy cyclophosphamide, etoposide, Adriamycin and methotrexate, and collateral sensitivity to vinca alkaloids and 5-fluorouracil. From these observations, the SBC-3/CDDP cells could be useful as a well characterized cisplatin-resistant cell line, and the resistance pattern in this cell line will give us much information for eradication of cisplatin-resistant tumor cells.
KW - 5-fluorouracil
KW - Cisplatin
KW - Glutathione
KW - Glutathione S-transferase
KW - Small-cell lung cancer
KW - Topoisomerase I and II
KW - Vinca alkaloids
KW - Π
UR - http://www.scopus.com/inward/record.url?scp=0031813382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031813382&partnerID=8YFLogxK
M3 - Article
C2 - 9615743
AN - SCOPUS:0031813382
SN - 0250-7005
VL - 18
SP - 927
EP - 933
JO - Anticancer research
JF - Anticancer research
IS - 2 A
ER -
